Management of Uncontrolled Hypertension

Critical Guideline Violation

Hydralazine should never be used as monotherapy or without a nitrate in patients with heart failure or significant cardiovascular disease, as stated by the American Heart Association, which explicitly classifies hydralazine without a nitrate as Class III Harm (should not be used) in patients with cardiovascular disease 1, 2
The American Heart Association recommends against the use of hydralazine monotherapy due to its potential harm in patients with cardiovascular disease 1

The American College of Cardiology recommends increasing hydralazine to 50 mg three times daily for optimal blood pressure control in patients with resistant hypertension 3
Higher doses of hydralazine, up to 50 mg twice daily, are supported by guidelines for effective blood pressure management in resistant hypertension 3

The American Heart Association recommends adding a thiazide-like diuretic, such as chlorthalidone 12.5-25 mg daily, as the foundational antihypertensive agent for patients with uncontrolled hypertension 1, 3
The American College of Cardiology suggests adding an ACE inhibitor (e.g., lisinopril 10-20 mg daily) or an ARB (e.g., losartan 50 mg daily) for cardiovascular protection in patients with a history of stroke and atrial fibrillation 1, 2
These agents provide mortality benefit beyond blood pressure reduction in patients with cardiovascular disease, according to the American Heart Association 1, 2

The American College of Cardiology recommends exercising extreme caution when initiating ACE inhibitors or ARBs in patients with a history of acute kidney failure and chronic kidney disease, and to start at low doses and monitor creatinine and potassium within 1-2 weeks 1, 3, 4
If eGFR <30 mL/min, loop diuretics (furosemide) should replace thiazide diuretics for volume control, as recommended by the American Heart Association, although they are less effective for blood pressure reduction 1, 2

The American Heart Association recommends targeting a blood pressure of <130/80 mmHg for patients with cardiovascular disease and stroke history, but to avoid dropping diastolic blood pressure below 60 mmHg to prevent cerebral hypoperfusion 2, 3
The American College of Cardiology suggests reassessing blood pressure within 2-4 weeks of medication adjustment 4

The American Heart Association emphasizes the importance of confirming medication adherence before escalating therapy, as therapeutic inertia and non-adherence are common causes of uncontrolled hypertension 5
The American College of Cardiology recommends considering home blood pressure monitoring or 24-hour ambulatory monitoring to exclude white-coat hypertension, with a target home blood pressure of <135/85 mmHg 3, 4

The American College of Cardiology advises against adding non-dihydropyridine calcium channel blockers (verapamil, diltiazem) in patients with atrial fibrillation and potential heart failure, as they are Class III contraindicated 1, 2
The American Heart Association recommends avoiding the combination of an ACE inhibitor with an ARB, as it increases the risk of hyperkalemia and acute kidney injury without benefit, particularly in patients with existing chronic kidney disease 3

The American College of Cardiology suggests adding spironolactone 12.5-25 mg daily as the fourth agent if blood pressure remains uncontrolled on optimized triple therapy, but notes that spironolactone is contraindicated if serum creatinine ≥2.5 mg/dL in men or ≥2.0 mg/dL in women, or if potassium ≥5.0 mEq/L 1, 3, 4
The American Heart Association recommends monitoring potassium and creatinine 1-2 weeks after initiating spironolactone, especially with concurrent ACE inhibitor/ARB use 3, 4

The American Heart Association recommends sodium restriction to <2 g/day (87 mmol/day) to reduce blood pressure by 10-20 mmHg in volume-dependent hypertension, particularly in patients with a history of heart failure risk factors and renal disease 1, 3